131 related articles for article (PubMed ID: 37247931)
1. Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma.
Sekine M; Koh I; Nakamoto K; Nosaka S; Tomono K; Sugimoto J; Kudo Y
Anticancer Res; 2023 Jun; 43(6):2509-2517. PubMed ID: 37247931
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.
Ohshima Y; Kaira K; Yamaguchi A; Oriuchi N; Tominaga H; Nagamori S; Kanai Y; Yokobori T; Miyazaki T; Asao T; Tsushima Y; Kuwano H; Ishioka NS
Cancer Sci; 2016 Oct; 107(10):1499-1505. PubMed ID: 27465934
[TBL] [Abstract][Full Text] [Related]
3. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Fan X; Ross DD; Arakawa H; Ganapathy V; Tamai I; Nakanishi T
Biochem Pharmacol; 2010 Sep; 80(6):811-8. PubMed ID: 20510678
[TBL] [Abstract][Full Text] [Related]
4. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T
Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1).
Kongpracha P; Nagamori S; Wiriyasermkul P; Tanaka Y; Kaneda K; Okuda S; Ohgaki R; Kanai Y
J Pharmacol Sci; 2017 Feb; 133(2):96-102. PubMed ID: 28242177
[TBL] [Abstract][Full Text] [Related]
6. Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
Kaji M; Kabir-Salmani M; Anzai N; Jin CJ; Akimoto Y; Horita A; Sakamoto A; Kanai Y; Sakurai H; Iwashita M
Int J Gynecol Cancer; 2010 Apr; 20(3):329-36. PubMed ID: 20375792
[TBL] [Abstract][Full Text] [Related]
7. The Adipose Tissue-Derived Secretome (ADS) in Obesity Uniquely Induces L-Type Amino Acid Transporter 1 (LAT1) and mTOR Signaling in Estrogen-Receptor-Positive Breast Cancer Cells.
Thompson C; Rahman MM; Singh S; Arthur S; Sierra-Bakhshi C; Russell R; Denning K; Sundaram U; Salisbury T
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201429
[TBL] [Abstract][Full Text] [Related]
8. L-Type Amino Acid Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1 Ligand 1 in Lung Cancer Cells.
Liu YH; Li YL; Shen HT; Chien PJ; Sheu GT; Wang BY; Chang WW
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681614
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
11. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling.
Nagamori S; Wiriyasermkul P; Okuda S; Kojima N; Hari Y; Kiyonaka S; Mori Y; Tominaga H; Ohgaki R; Kanai Y
Amino Acids; 2016 Apr; 48(4):1045-1058. PubMed ID: 26724922
[TBL] [Abstract][Full Text] [Related]
13. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract][Full Text] [Related]
14. L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells.
Satou M; Wang J; Nakano-Tateno T; Teramachi M; Suzuki T; Hayashi K; Lamothe S; Hao Y; Kurata H; Sugimoto H; Chik C; Tateno T
Mol Cell Endocrinol; 2020 Sep; 515():110868. PubMed ID: 32579901
[TBL] [Abstract][Full Text] [Related]
15. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract][Full Text] [Related]
16. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
[TBL] [Abstract][Full Text] [Related]
17. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Nagamori S; Promchan K; Nakajima T; Yamamoto N; Mori M; Kanai Y
Anticancer Res; 2010 Dec; 30(12):4819-28. PubMed ID: 21187458
[TBL] [Abstract][Full Text] [Related]
19. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
20. Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma.
Sato K; Miyamoto M; Takano M; Furuya K; Tsuda H
Virchows Arch; 2019 Jun; 474(6):701-710. PubMed ID: 30637450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
